Erratum to ‘Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making’

The publishers would like to sincerely apologize for any inconvenience caused by the error introduced to ‘Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making’ by Gerhard H. Scholz and Holger Fleischmann, which was published in Therapeutic Advances in Endocrinology and Metabolism 2014, Vol. 5(5): 95–123, DOI: 10.1177/2042018814556099.

The error appears in the title, keywords, abstract, introduction and in the Figures 2 and 3 descriptions of this paper. GLP-1 was expanded to glucagon-like protein 1, when it should read glucagon-like peptide-1.